Copyright
©The Author(s) 2021.
World J Virol. Mar 25, 2021; 10(2): 53-61
Published online Mar 25, 2021. doi: 10.5501/wjv.v10.i2.53
Published online Mar 25, 2021. doi: 10.5501/wjv.v10.i2.53
Table 2 Primary and secondary outcomes of studies included in simmons’ meta-analysis
| Intervention arm (92 patients) | Control arm (84 patients) | |||
| Outcomes | Primary | Clinical recovery in 14 d | 86 (93%) | 57 (68%) |
| All cause mortality | 5 (5%) | 17 (20%) | ||
| Secondary | Duration of hospitalization | 6 (IQR: 5-7) | 8 (IQR: 6-11) | |
| ICU admission/imv needed | 9 (10%) | 24 (29%) |
- Citation: Spera AM. Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review. World J Virol 2021; 10(2): 53-61
- URL: https://www.wjgnet.com/2220-3249/full/v10/i2/53.htm
- DOI: https://dx.doi.org/10.5501/wjv.v10.i2.53